Albendazole Dosage

This dosage information may not include all the information needed to use Albendazole safely and effectively. See additional information for Albendazole.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for Hydatid Disease

Cystic hydatid disease of the liver, lung, and peritoneum due to Echinococcus granulosus:
60 kg or more: 400 mg orally twice a day with meals
Less than 60 kg: 15 mg/kg/day orally, given in divided doses twice a day with meals (maximum dose: 800 mg/day)

Duration: 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles

When administering albendazole in the presurgical or postsurgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

Usual Adult Dose for Neurocysticercosis

Parenchymal neurocysticercosis:
60 kg or more: 400 mg orally twice a day with meals
Less than 60 kg: 15 mg/kg/day orally, given in divided doses twice a day with meals (maximum dose: 800 mg/day)

Duration: 8 to 30 days

Usual Adult Dose for Cutaneous Larva Migrans

400 mg orally once a day for 3 days

Case Report (4)
400 mg orally twice a day for 3 days; in some of the reports therapy was continued for 5 days

Usual Adult Dose for Ascariasis

400 mg orally once as a single dose

Usual Adult Dose for Trichostrongylosis

400 mg orally once as a single dose

Usual Adult Dose for Pinworm Infection (Enterobius vermicularis)

400 mg orally once as a single dose; may repeat in 2 weeks

Some clinicians recommend all household contacts of patients with enterobiasis receive treatment, especially when multiple or repeated symptomatic infections occur, since such contacts commonly also are infected.

Usual Adult Dose for Filariasis

Due to Mansonella perstans: 400 mg orally twice a day for 10 days

Usual Adult Dose for Hookworm Infection (Necator or Ancylostoma)

Intestinal infections due to A duodenal or N americanus: 400 mg orally once as a single dose; stool examination for eggs should be repeated 2 weeks after treatment and dose should be repeated if positive

Eosinophilic enterocolitis due to A caninum: 400 mg orally once as a single dose

Usual Adult Dose for Visceral Larva Migrans (Toxicariasis)

400 mg orally twice a day for 5 days; however, optimum duration is unknown and some clinicians recommend treatment for up to 20 days

Usual Adult Dose for Strongyloidiasis

400 mg orally twice a day for 2 days; may be necessary to repeat or prolong treatment or use other agents in immunocompromised patients or patients with disseminated disease

Usual Adult Dose for Trichinosis

400 mg orally twice a day for 8 to 14 days

Usual Adult Dose for Whipworm Infection (Trichuris trichiura)

400 mg orally once a day for 3 days

Usual Adult Dose for Capillariasis

400 mg orally once a day for 10 days

Usual Adult Dose for Gnathostomiasis

400 mg orally twice a day for 21 days

Usual Adult Dose for Clornorchis sinensis (Liver Fluke)

10 mg/kg orally once a day for 7 days

Usual Adult Dose for Giardiasis

400 mg orally once a day for 5 days; may be given alone or in combination with metronidazole

Usual Adult Dose for Cysticercus cellulosae (Cysticercosis)

400 mg orally twice a day for 8 to 30 days; may repeat as necessary

Usual Adult Dose for Echinococcus Infection

E granulosus: 400 mg orally twice a day for 1 to 6 months

Usual Adult Dose for Microsporidiosis

Disseminated: 400 mg orally twice a day
Intestinal: 400 mg orally twice a day for 21 days
Ocular: 400 mg orally twice a day in combination with fumagillin (not commercially available in the US)

Usual Pediatric Dose for Hydatid Disease

Cystic hydatid disease of the liver, lung, and peritoneum due to Echinococcus granulosus:
60 kg or more: 400 mg orally twice a day with meals
Less than 60 kg: 15 mg/kg/day orally, given in divided doses twice a day with meals (maximum dose: 800 mg/day)

Duration: 28-day cycle followed by a 14-day albendazole-free interval, for a total of 3 cycles

When administering albendazole in the presurgical or postsurgical setting, optimal killing of cyst contents is achieved when 3 courses of therapy have been given.

Usual Pediatric Dose for Neurocysticercosis

Parenchymal neurocysticercosis:
60 kg or more: 400 mg orally twice a day with meals
Less than 60 kg: 15 mg/kg/day orally, given in divided doses twice a day with meals (maximum dose: 800 mg/day)

Duration: 8 to 30 days

Usual Pediatric Dose for Capillariasis

400 mg orally once a day for 10 days

Case Reports (n=2)
Greater than 18 months: 400 mg per day for 21 days, up to 100 days

Usual Pediatric Dose for Cutaneous Larva Migrans

400 mg orally once a day for 3 days

Case Report (n=1)
11 months: 2.5 mL (suspension: 200 mg/5 mL) orally twice a day for 3 days

Usual Pediatric Dose for Cysticercus cellulosae (Cysticercosis)

15 mg/kg/day orally, given in divided doses twice a day for 8 to 30 days; may repeat as necessary
Maximum dose: 800 mg/day

Usual Pediatric Dose for Echinococcus Infection

E granulosus: 15 mg/kg/day orally, given in divided doses twice a day for 1 to 6 months
Maximum dose: 800 mg/day

Usual Pediatric Dose for Ascariasis

400 mg orally once as a single dose

Usual Pediatric Dose for Trichostrongylosis

400 mg orally once as a single dose

Usual Pediatric Dose for Pinworm Infection (Enterobius vermicularis)

400 mg orally once as a single dose; may repeat in 2 weeks

Some clinicians recommend all household contacts of patients with enterobiasis receive treatment, especially when multiple or repeated symptomatic infections occur, since such contacts commonly also are infected.

Usual Pediatric Dose for Filariasis

Due to Mansonella perstans: 400 mg orally twice a day for 10 days

Usual Pediatric Dose for Hookworm Infection (Necator or Ancylostoma)

Intestinal infections due to A duodenal or N americanus: 400 mg orally once as a single dose; stool examination for eggs should be repeated 2 weeks after treatment and dose should be repeated if positive

Eosinophilic enterocolitis due to A caninum: 400 mg orally once as a single dose

Usual Pediatric Dose for Visceral Larva Migrans (Toxicariasis)

400 mg orally twice a day for 5 days; however, optimum duration is unknown and some clinicians recommend treatment for up to 20 days

Usual Pediatric Dose for Strongyloidiasis

400 mg orally twice a day for 2 days; may be necessary to repeat or prolong treatment or use other agents in immunocompromised patients or patients with disseminated disease

Usual Pediatric Dose for Trichinosis

400 mg orally twice a day for 8 to 14 days

Usual Pediatric Dose for Whipworm Infection (Trichuris trichiura)

400 mg orally once a day for 3 days

Usual Pediatric Dose for Gnathostomiasis

400 mg orally twice a day for 21 days

Usual Pediatric Dose for Clornorchis sinensis (Liver Fluke)

10 mg/kg orally once a day for 7 days

Usual Pediatric Dose for Giardiasis

400 mg orally once a day for 5 days; may be given alone or in combination with metronidazole

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Rare fatalities associated with albendazole use have been reported due to granulocytopenia or pancytopenia. Bone marrow suppression, aplastic anemia, and agranulocytosis in patients with and without underlying hepatic dysfunction have been observed with albendazole. Occasional reversible reductions in total white blood cell count have also been reported with albendazole. Blood counts should be monitored at the start of each 28-day treatment cycle, and every 2 weeks while on albendazole in all patients. Patients with liver disease, including hepatic echinococcosis, appear to be more susceptible to bone marrow suppression leading to pancytopenia, aplastic anemia, agranulocytosis, and leukopenia and therefore require closer monitoring of blood counts. Albendazole should be discontinued in all patients if clinically significant decreases in blood cell counts occur.

In clinical trials, albendazole has been associated with mild to moderate elevations of hepatic enzymes. These elevations have generally returned to normal upon discontinuation of albendazole therapy. There have also been reports of acute liver failure of uncertain causality and hepatitis. Liver function tests (transaminases) should be performed before the start of each treatment cycle and at least every 2 weeks during therapy. If hepatic enzymes exceed twice the upper limit of normal, discontinuation of albendazole treatment should be considered based on individual patient circumstances. Restarting albendazole treatment in patients whose hepatic enzymes have normalized off treatment is an individual decision that should take into account the risk/benefit of further albendazole usage. Laboratory tests should be performed frequently if albendazole treatment is restarted. Patients with abnormal liver function test results are at risk for hepatotoxicity and bone marrow suppression. Therapy should be discontinued if liver enzymes are significantly increased or if clinically significant decreases in blood cell counts occur.

Patients being treated for neurocysticercosis should receive anticonvulsant and steroid therapy as required. Corticosteroids (oral or IV) should be considered to prevent cerebral hypertensive episodes during the first week of treatment.

Preexisting neurocysticercosis may be found in patients treated with albendazole for other conditions. If patients experience neurological symptoms soon after treatment due to an inflammatory reaction caused by parasitic death within the brain, appropriate steroid and anticonvulsant therapy should be started at once.

Cysticercosis may involve the retina in rare cases. Before starting neurocysticercosis therapy, the patient should be examined for retinal lesions. If such lesions are present, the need for anticysticeral therapy should be weighed against the possibility of retinal damage caused by albendazole-induced changes to the retinal lesion.

Pregnant women should not use albendazole except in clinical circumstances where no alternative therapy is appropriate. Women of childbearing age should begin treatment after a negative pregnancy test and should be cautioned against becoming pregnant during or within 1 month of completing albendazole treatment. If pregnancy occurs while taking albendazole, therapy should be discontinued at once and the patient should be apprised of the potential risk to the fetus.

Dialysis

Data not available

Other Comments

Albendazole should be administered with food. Administration of albendazole with a fatty meal (fat content 43.1 g) has shown an increase in plasma concentrations of albendazole sulfoxide in a dose-proportional manner over the therapeutic dose range.

In patients who have difficulty swallowing the tablets whole, the tablets should be crushed or chewed and swallowed with a little water.

Hide
(web4)